Compare with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES IPCA LABS ALKEM LABORATORIES/
IPCA LABS
 
P/E (TTM) x 22.4 21.6 103.5% View Chart
P/BV x 5.4 7.7 69.8% View Chart
Dividend Yield % 0.9 0.2 573.2%  

Financials

 ALKEM LABORATORIES   IPCA LABS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
IPCA LABS
Mar-19
ALKEM LABORATORIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,7201,042 261.0%   
Low Rs1,660590 281.4%   
Sales per share (Unadj.) Rs697.9298.6 233.7%  
Earnings per share (Unadj.) Rs96.135.0 274.6%  
Cash flow per share (Unadj.) Rs117.349.4 237.2%  
Dividends per share (Unadj.) Rs25.003.00 833.3%  
Dividend yield (eoy) %1.10.4 310.5%  
Book value per share (Unadj.) Rs515.2247.1 208.5%  
Shares outstanding (eoy) m119.57126.35 94.6%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.12.7 114.8%   
Avg P/E ratio x22.823.3 97.7%  
P/CF ratio (eoy) x18.716.5 113.2%  
Price / Book Value ratio x4.33.3 128.7%  
Dividend payout %26.08.6 303.4%   
Avg Mkt Cap Rs m261,879103,108 254.0%   
No. of employees `00014.313.4 106.6%   
Total wages/salary Rs m15,0557,874 191.2%   
Avg. sales/employee Rs Th5,822.62,807.0 207.4%   
Avg. wages/employee Rs Th1,050.5585.8 179.3%   
Avg. net profit/employee Rs Th802.0329.0 243.8%   
INCOME DATA
Net Sales Rs m83,44437,732 221.1%  
Other income Rs m1,042577 180.7%   
Total revenues Rs m84,48638,309 220.5%   
Gross profit Rs m14,7346,901 213.5%  
Depreciation Rs m2,5281,824 138.6%   
Interest Rs m651189 344.8%   
Profit before tax Rs m12,5985,465 230.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1051,042 106.0%   
Profit after tax Rs m11,4934,422 259.9%  
Gross profit margin %17.718.3 96.5%  
Effective tax rate %8.819.1 46.0%   
Net profit margin %13.811.7 117.5%  
BALANCE SHEET DATA
Current assets Rs m54,96023,778 231.1%   
Current liabilities Rs m32,43310,975 295.5%   
Net working cap to sales %27.033.9 79.6%  
Current ratio x1.72.2 78.2%  
Inventory Days Days80104 76.7%  
Debtors Days Days7266 109.4%  
Net fixed assets Rs m32,71020,368 160.6%   
Share capital Rs m239253 94.6%   
"Free" reserves Rs m61,36830,971 198.1%   
Net worth Rs m61,60731,224 197.3%   
Long term debt Rs m1,5921,409 113.1%   
Total assets Rs m99,43345,507 218.5%  
Interest coverage x20.430.0 68.0%   
Debt to equity ratio x00 57.3%  
Sales to assets ratio x0.80.8 101.2%   
Return on assets %12.210.1 120.5%  
Return on equity %18.714.2 131.7%  
Return on capital %21.017.3 121.0%  
Exports to sales %19.145.9 41.6%   
Imports to sales %3.016.6 17.9%   
Exports (fob) Rs m15,91717,308 92.0%   
Imports (cif) Rs m2,4836,266 39.6%   
Fx inflow Rs m16,06117,308 92.8%   
Fx outflow Rs m2,4836,266 39.6%   
Net fx Rs m13,57811,042 123.0%   
CASH FLOW
From Operations Rs m5,8514,923 118.9%  
From Investments Rs m-7,414-1,563 474.3%  
From Financial Activity Rs m792-1,832 -43.2%  
Net Cashflow Rs m-7311,528 -47.9%  

Share Holding

Indian Promoters % 66.9 45.9 145.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 11.4 290.4%  
FIIs % 0.0 25.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.4 -  
Shareholders   68,381 36,892 185.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; Dow Futures Down by 39 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 160 points, down 0.3% at 50,685 levels.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 5, 2021 01:20 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS